Patents by Inventor Timothy Gahman

Timothy Gahman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10752612
    Abstract: Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: August 25, 2020
    Assignee: LUDWIG INSTITUTE FOR CANCER RESEARCH LTD
    Inventors: Timothy Gahman, Andrew Shiau
  • Publication number: 20200237763
    Abstract: Described inter alia are compounds according to formula (I): or a pharmaceutically acceptable salt thereof, and uses in methods for the modulation of flap endonuclease 1 (FEN1), Xeroderma Pigmentosum Complementation Group G protein (XPG), Exonuclease 1 (EXO1) and/or GEN1.
    Type: Application
    Filed: September 26, 2016
    Publication date: July 30, 2020
    Inventors: Timothy Gahman, Andrew Shiau, Richard Kolodner
  • Publication number: 20180086739
    Abstract: Provided herein, inter alia, are compounds and methods for inhibiting PLK4 and for treating cancer in a subject in need thereof.
    Type: Application
    Filed: April 15, 2016
    Publication date: March 29, 2018
    Inventors: Timothy Gahman, Andrew Shiau
  • Publication number: 20090209536
    Abstract: The present invention relates to compounds and methods useful as modulators of CB2 for the treatment or prevention of disease states including, but not limited to pain, autoimmune disease, malabsorption syndrome, pulmonary disease, osteoporosis, muscle spasm in cancer, neuromuscular disorder, and atherosclerosis progression.
    Type: Application
    Filed: June 16, 2008
    Publication date: August 20, 2009
    Applicant: KALYPSYS, INC.
    Inventors: Timothy Gahman, David Thomas, Hengyuan Lang, Mark Eben Massari
  • Publication number: 20070197609
    Abstract: The present invention relates to novel salts and methods useful as inhibitors of the nitric oxide synthase.
    Type: Application
    Filed: November 25, 2006
    Publication date: August 23, 2007
    Applicant: KALYPSYS, INC.
    Inventors: Brett Cowans, Patricia Mougin-Andres, Patrick Wheeler, Timothy Gahman, Mark Herbert
  • Publication number: 20070155746
    Abstract: The present invention relates to compounds and methods useful as inhibitors of protein kinases, including B-Raf and several receptor tyrosine and cytoplasmic tyrosine kinases. The present invention is directed to new substituted pyrimidinyloxy urea compounds of Formulas II, III and IV and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulating of protein kinase activity in a human or animal subject are also provided for the treatment diseases such as cancers.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 5, 2007
    Applicant: KALYPSYS, INC.
    Inventors: Hengyuan Lang, Timothy Gahman, Mark Herbert, Paul Wash, Cunxiang Zhao, Robert Davis
  • Publication number: 20070155764
    Abstract: The present invention relates to compounds and methods useful as inhibitors of protein kinases, including B-Raf and several receptor tyrosine and cytoplasmic tyrosine kinases. The present invention is directed to new substituted pyrimidinyloxy urea compounds of Formulas II, III and IV and compositions and their application as pharmaceuticals for the treatment of disease. Methods of modulating of protein kinase activity in a human or animal subject are also provided for the treatment diseases such as cancers.
    Type: Application
    Filed: December 22, 2006
    Publication date: July 5, 2007
    Applicant: KALYPSYS, INC.
    Inventors: Hengyuan Lang, Timothy Gahman, Mark Herbert, Paul Wash, Cunxiang Zhao, Robert Davis
  • Publication number: 20070123572
    Abstract: The present invention discloses a novel method for preparing 3-imidazol-1-yl-[1,2,4]thiadiazole derivatives, particularly to a method of preparing 5-halo-3-imidazol-1-yl-[1,2,4]thiadiazole, more particularly (3 -imidazol-1-yl-[1,2,4]thiadiazol-5-yl)-dialkyl-amines, that afford a high yield of pure product.
    Type: Application
    Filed: November 25, 2006
    Publication date: May 31, 2007
    Applicant: KALYPSYS, INC.
    Inventors: Mark Herbert, Russell Cousins, Hengyuan Lang, Timothy Gahman, Stewart Noble
  • Publication number: 20070049591
    Abstract: The present invention relates to compounds useful as inhibitors of MEK kinase and methods for the treatment or prevention of cellular proliferative disease states, such as conditions related to the hyperactivity of MEK, as well as diseases modulated by the MEK cascade.
    Type: Application
    Filed: August 24, 2006
    Publication date: March 1, 2007
    Inventors: Anthony Pinkerton, Robert Davis, Timothy Gahman, J. Semple
  • Publication number: 20060116515
    Abstract: The present invention relates to compounds and methods useful as inhibitors of nitric oxide synthase. Certain compounds of the subject invention have the following structural formula: wherein T, X, and Y are independently selected from the group consisting of CR4, N, NR4, S, and O; U is selected from the group consisting of CR10 and N; V is selected from the group consisting of CR4 and N; W and W? are independently selected from the group consisting of CH2, CR7R8, NR9, O, N(O), S(O)q and C(O); n, m and p are independently an integer from 0 to 5; q is 0, 1, or 2; and other substituents are as defined herein. Other compounds of the subject invention have structural formulas as defined herein. Also disclosed herein are pharmaceutical compositions comprising the compounds of the subject invention.
    Type: Application
    Filed: November 28, 2005
    Publication date: June 1, 2006
    Inventors: Timothy Gahman, Hengyuan Lang, Mark Herbert, Angelina Thayer, Christian Hassig, Stewart Noble, Russell Cousins, Hui Zhuang, Christopher Santos, Xiaohong Chen